Quanterix Corporation (QTRX)
NASDAQ: QTRX · Real-Time Price · USD
5.99
-0.13 (-2.12%)
At close: Feb 11, 2026, 4:00 PM EST
5.97
-0.02 (-0.40%)
After-hours: Feb 11, 2026, 6:07 PM EST
Quanterix Employees
Quanterix had 471 employees as of December 31, 2024. The number of employees increased by 30 or 6.80% compared to the previous year.
Employees
471
Change (1Y)
30
Growth (1Y)
6.80%
Revenue / Employee
$276,439
Profits / Employee
-$203,102
Market Cap
279.80M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 471 | 30 | 6.80% |
| Dec 31, 2023 | 441 | 71 | 19.19% |
| Dec 31, 2022 | 370 | -90 | -19.57% |
| Dec 31, 2021 | 460 | 146 | 46.50% |
| Dec 31, 2020 | 314 | 66 | 26.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Viemed Healthcare | 1,380 |
| RxSight | 498 |
| 908 Devices | 246 |
| Sight Sciences | 216 |
| Electromed | 180 |
| Profound Medical | 142 |
| Senseonics Holdings | 117 |
| TriSalus Life Sciences | 110 |
QTRX News
- 8 days ago - Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection - Business Wire
- 21 days ago - Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling - Business Wire
- 26 days ago - Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 - Business Wire
- 7 weeks ago - Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence - Business Wire
- 2 months ago - Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth - Business Wire
- 3 months ago - Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring - Business Wire
- 3 months ago - Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript - Seeking Alpha